GSK measles vaccine gets U.S. FDA approval
Send a link to a friend
[June 06, 2022]
(Reuters) -British drugmaker GSK
said on Monday its vaccine, Priorix, was approved by the U.S. Food and
Drug Administration (FDA) for the prevention of measles, mumps and
rubella (MMR) in those aged one year and above.
The vaccine can be given as two doses, and may also be administered as a
second shot to individuals who were previously vaccinated with a first
dose of another MMR-containing vaccine, GSK said.
Child vaccination rates in the United States fell during the COVID-19
pandemic as many children skipped doctor appointments and states eased
vaccine requirements during remote learning, according to a government
study https://www.reuters.com/world/us/us-child-vaccination-rates-dip-during-pandemic-study-2022-04-21
released last month.
"We're proud to make Priorix available in the U.S. for the first time,
adding a choice for providers to help protect patients against these
highly-contagious diseases," GSK Head of U.S. Vaccines Judy Stewart
said.
[to top of second column]
|
GSK logo is seen in this illustration taken on January 17, 2022.
REUTERS/Dado Ruvic/Illustration
In recent years, measles outbreaks
have occurred globally with more than 400,000 cases confirmed in
2019 - a setback in the progress towards eliminating the disease in
many countries.
Priorix, Priorix Tetra and chickenpox vaccine Varilrix contributed
about 260 million pounds ($325.99 million) to GSK's vaccines
turnover last year.
GSK, which is spinning off its consumer health business, is
sharpening its focus on vaccines and prescription drugs.
($1 = 0.7976 pounds)
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry
Jacob-Phillips)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |